Mineralys Therapeutics, Inc. (MLYS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.5x

Market Cap

$2.49B

MomentumView details →

1D Return

−0.21%

YTD Return

−23.89%

RSI (14)

55.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.5x

Market Cap

$2.49B

RSI (14)

55.7

MomentumView details →

1D Return

−0.21%

YTD Return

−23.89%

SummaryUpdated Jun 1, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Radnor, Pennsylvania. The company went public in February 2023 and focuses on developing innovative therapies for hypertension and associated cardiovascular diseases. Mineralys is currently advancing its lead drug candidate, lorundrostat, through multiple Phase III clinical trials targeting patients with uncontrolled and resistant hypertension, representing a significant unmet medical need affecting millions of patients worldwide.

Ask drillr about Mineralys Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−63.45%

ROA (TTM)

−52.34%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−19.10%

FCF YoY

+27.98%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+37.43%

EBITDA YoY

−77.16%

EarningsView details →

EPS (Actual)

−$2.85

EPS Surprise

−419.53%

Beats (12Q)

6/12

Next Q EPS Est

−$0.55

Avg Surprise (4Q)

−93.45%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

34.46x

Quick Ratio

34.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−349.58M

Op. CF (TTM)

−138.79M

Next earningsNov 9, 2026 →

Latest newsMore news →

Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.24d ago

Mineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer to lead medical and late-stage clinical activities.24d ago

Similar companies

Pharvaris N.V.PHVS Harmony Biosciences Holdings, Inc.HRMY Trevi Therapeutics, Inc.TRVI Nektar TherapeuticsNKTR Shanghai Bao Pharmaceuticals Co., Ltd.02659.HK Precigen, Inc.PGEN Find similar companies →

Latest newsMore news →

Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.24d ago Mineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer to lead medical and late-stage clinical activities.24d ago